A synergistic multitargeted of BET and HDAC: an intra-molecular mechanism of communication in treatment of Waldenström macroglobulinemia

References

• Kapoor P, Paludo J, Vallumsetla N, et al. Waldenström macroglobulinemia: what a hematologist needs to know. Blood Rev. 2015;29(5):301–319.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Kyle RA, Reeder CB, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010;85(9):824–833.
   PubMed Web of Science ®Google Scholar
• Treon SP, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naïve patients With Waldenström macroglobulinemia. J Clin Oncol. 2018;36(27):2755–2761.
   PubMed Web of Science ®Google Scholar
• Han W, Matissek SJ, Jackson DA, et al. Targeting IL-6 receptor reduces IgM levels and tumor growth in Waldenström macroglobulinemia. Oncotarget. 2019;10(36):3400–3407.
   PubMedGoogle Scholar
• Sun JY, Xu L, Tseng H, et al. Histone deacetylase inhibitors demonstrate significant Preclinical activity as single agents, and in combination with Bortezomib in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011;11(1):152–156.
   PubMed Web of Science ®Google Scholar
• de Weerdt I, Koopmans SM, Kater AP, et al. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica. 2017;102(10):1629–1639.
   PubMed Web of Science ®Google Scholar
• Tate CR, Rhodes LV, Segar HC, et al. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res. 2012;14(3):R79.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Kouzarides T, Huntly BJP. Targeting epigenetic readers in cancer. New England J Med. 2012;367(7):647–657.
   PubMed Web of Science ®Google Scholar
• Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell. 2014;54(5):728–736.
   PubMed Web of Science ®Google Scholar
• Liu S, Li F, Pan L, et al. BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo. Cancer Sci. 2019;110(8):2493–2506.
   PubMed Web of Science ®Google Scholar
• Kim SR, Lewis JM, Cyrenne BM, et al. BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition. Oncotarget. 2018;9(49):29193–29207.
   PubMedGoogle Scholar
• Bhalla KN. Epigenetic and chromatin modifiers As targeted therapy of hematologic malignancies. J Clin Oncol. 2005;23(17):3971–3993.
   PubMed Web of Science ®Google Scholar
• Borbely G, Haldosen L-A, Dahlman-Wright K, et al. Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells. Oncotarget. 2015;6(32):33623–33635.
   PubMed Web of Science ®Google Scholar
• Kelly RDW, Cowley SM. The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. Biochem Soc Trans. 2013;41(3):741–749.
   PubMedGoogle Scholar
• Mosashvilli D, Kahl P, Mertens C, et al. Global histone acetylation levels: Prognostic relevance in patients with renal cell carcinoma. Cancer Sci. 2010;101(12):2664–2669.
   PubMed Web of Science ®Google Scholar
• Minardi D, Lucarini G, Filosa A, et al. Prognostic role of global DNA-methylation and histone acetylation in pT1a clear cell renal carcinoma in partial nephrectomy specimens. J Cell Mol Med. 2009;13(8b):2115–2121.
   PubMed Web of Science ®Google Scholar
• Elsheikh SE, Green AR, Rakha EA, et al. Global histone modifications in breast cancer correlate with tumor phenotypes, Prognostic factors, and patient outcome. Cancer Res. 2009;69(9):3802–3809.
   PubMed Web of Science ®Google Scholar
• Ebrahimi A, Schittenhelm J, Honegger J, et al. Prognostic relevance of global histone 3 lysine 9 acetylation in ependymal tumors. J Neurosurg. 2013;119(6):1424–1431.
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9):769–784.
   PubMed Web of Science ®Google Scholar
• Lovén J, Hoke HA, Lin CY, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153(2):320–334.
   PubMed Web of Science ®Google Scholar
• Lockwood WW, Zejnullahu K, Bradner JE, et al. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci. 2012;109(47):19408–19413.
   PubMed Web of Science ®Google Scholar
• Lee TI, Young RA. Transcriptional regulation and Its misregulation in disease. Cell. 2013;152(6):1237–1251.
   PubMed Web of Science ®Google Scholar
• Garnier J-M, Sharp PP, Burns CJ. BET bromodomain inhibitors: a patent review. Expert Opin Ther Pat. 2014;24(2):185–199.
   PubMed Web of Science ®Google Scholar
• Fiskus W, Sharma S, Qi J, et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther. 2014;13(5):1142–1154.
   PubMed Web of Science ®Google Scholar
• Amemiya S, Yamaguchi T, Hashimoto Y, et al. Synthesis and evaluation of novel dual BRD4/HDAC inhibitors. Bioorg Med Chem. 2017;25(14):3677–3684.
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067–1073.
   PubMed Web of Science ®Google Scholar
• Bhadury J, Nilsson LM, Veppil Muralidharan S, et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci. 2014;111(26):E2721–E2730.
   PubMed Web of Science ®Google Scholar
• Matissek SJ, Han W, Karbalivand M, et al. Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition. Epigenomics. 2021;13(2):129–144. Available from: https://www.futuremedicine.com/doi/https://doi.org/10.2217/epi-2020-0189.
   PubMedGoogle Scholar
• Boran ADW, Iyengar R. Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel. 2010;13(3):297–309.
   PubMed Web of Science ®Google Scholar
• Raghavendra NM, Pingili D, Kadasi S, et al. Dual or multi-targeting inhibitors: The next generation anticancer agents. Eur J Med Chem. 2018;143:1277–1300.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zegar T, Weiser T, et al. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. Int J Cancer. 2020;147(10):2847–2861.
   PubMed Web of Science ®Google Scholar
• Mokhtari RB, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–38043.
   PubMedGoogle Scholar
• Berman HM, Battistuz T, Bhat TN, et al. The protein data bank. Acta Crystallogr. Sect. D Biol. Crystallogr. 2002.
   Google Scholar
• Liu Z, Chen H, Wang P, et al. Discovery of orally bioavailable chromone derivatives as potent and Selective BRD4 inhibitors: scaffold hopping, optimization, and pharmacological evaluation. J Med Chem. 2020;63(10):5242–5256.
   PubMed Web of Science ®Google Scholar
• Finnin MS, Donigian JR, Cohen A, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 1999;401(6749):188–193.
   PubMed Web of Science ®Google Scholar
• Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera – a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–1612.
   PubMed Web of Science ®Google Scholar
• Kusumaningrum S, Budianto E, Kosela S, et al. The molecular docking of 1,4-naphthoquinone derivatives as inhibitors of Polo-like kinase 1 using Molegro virtual docker. J. Appl. Pharm. Sci. 2014.
   Google Scholar
• Thomsen R, Christensen MH. Moldock:  a new technique for high-accuracy molecular docking. J Med Chem. 2006;49(11):3315–3321.
   PubMed Web of Science ®Google Scholar
• Allouche A. Software news and updates Gabedit—a graphical user interface for computational chemistry softwares. J Comput Chem. 2012;32:174–182.
   Web of Science ®Google Scholar
• Trott O, Olson A. Autodock vina: improving the speed and accuracy of docking. J Comput Chem. 2010;31(2):455–461.
   PubMed Web of Science ®Google Scholar
• Madhavi Sastry G, Adzhigirey M, Day T, et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013;27(3):221–234.
   PubMed Web of Science ®Google Scholar
• Mhlongo NN, Ebrahim M, Skelton AA, et al. Dynamics of the thumb-finger regions in a GH11 xylanase bacillus circulans: comparison between the Michaelis and covalent intermediate. RSC Adv. 2015;5(100):82381–82394.
   Web of Science ®Google Scholar
• Ramharack P, Oguntade S, Soliman MES. Delving into Zika virus structural dynamics-a closer look at NS3 helicase loop flexibility and its role in drug discovery. RSC Adv. 2017;7(36):22133–22144.
   Web of Science ®Google Scholar
• Case DA, Walker RC, Cheatham TE, et al. (2018). Amber 2018. University of California, San Francisco; 2018, 1–923. Available from: http://ambermd.org/doc12/Amber18.pdf.
   Google Scholar
• Wang J, Wolf RM, Caldwell JW, et al. Development and testing of a general amber force field. J Comput Chem. 2004;25:1157–1174.
   PubMed Web of Science ®Google Scholar
• Grest GS, Kremer K. Molecular dynamics simulation for polymers in the presence of a heat bath. Phys Rev A. 1986;33(5):3628–3631.
   PubMed Web of Science ®Google Scholar
• Berendsen HJC, Postma JPM, Van Gunsteren WF, et al. Molecular dynamics with coupling to an external bath. J Chem Phys. 1984;81(8):3684–3690.
   Web of Science ®Google Scholar
• Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys. 1977;23(3):327–341.
   Web of Science ®Google Scholar
• Roe DR, Cheatham TE. PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput. 2013;9(7):3084–3095.
   PubMed Web of Science ®Google Scholar
• Seifert E. Originpro 9.1: scientific data analysis and graphing software – software review. J. Chem. Inf. Model. 2014;54(5):1552–1552.
   PubMed Web of Science ®Google Scholar
• Abdullahi M, Olotu FA, Soliman ME. Dynamics of allosteric modulation of lymphocyte function associated antigen-1 closure-open switch: unveiling the structural mechanisms associated with outside-in signaling activation. Biotechnol Lett. 2017;39(12):1843–1851.
   PubMed Web of Science ®Google Scholar
• Olotu FA, Soliman MES. From mutational inactivation to aberrant gain-of-function: unraveling the structural basis of mutant p53 oncogenic transition. J Cell Biochem. 2018;119(3):2646–2652.
   PubMed Web of Science ®Google Scholar
• Wan H, Hu JP, Tian XH, et al. Molecular dynamics simulations of wild type and mutants of human complement receptor 2 complexed with C3d. Phys Chem Chem Phys. 2013;15(4):1241–1251. Available from: http://xlink.rsc.org/?DOI=C2CP41388D.
   PubMed Web of Science ®Google Scholar
• Chang S, Hu JP, Lin PY, et al. Substrate recognition and transport behavior analyses of amino acid antiporter with coarse-grained models. Mol Biosyst. 2010;6(12):2430–2438. Available from: http://xlink.rsc.org/?DOI=c005266c.
   PubMedGoogle Scholar
• Fakhar Z, Govender T, Maguire GEM, et al. Differential flap dynamics in l,d-transpeptidase2 from mycobacterium tuberculosis revealed by molecular dynamics. Mol Biosyst. 2017;13(6):1223–1234. Available from: http://xlink.rsc.org/?DOI=C7MB00110J.
   PubMedGoogle Scholar
• David CC, Jacobs DJ. Principal component analysis: a method for determining the essential dynamics of proteins. Protein Dynamics. 2014: 193–226. Available from: http://link.springer.com/https://doi.org/10.1007/978-1-62703-658-0_11.
   Google Scholar
• Levy RM, Srinivasan AR, Olson WK, et al. Quasi-harmonic method for studying very low frequency modes in proteins. Biopolymers. 1984;23(6):1099–1112. Available from: https://onlinelibrary.wiley.com/doi/https://doi.org/10.1002/bip.360230610.
   PubMed Web of Science ®Google Scholar
• Chen J, Wang J, Zhu W. Binding modes of three inhibitors 8CA, F8A and I4A to A-FABP studied based on molecular dynamics simulation. PLoS One. 2014;9(6):e99862. Available from: https://dx.plos.org/https://doi.org/10.1371/journal.pone.0099862.
   PubMed Web of Science ®Google Scholar
• Ichiye T, Karplus M. Collective motions in proteins: A covariance analysis of atomic fluctuations in molecular dynamics and normal mode simulations. Proteins Struct Funct Genet. 1991;11(3):205–217. Available from: https://onlinelibrary.wiley.com/doi/https://doi.org/10.1002/prot.340110305.
   PubMed Web of Science ®Google Scholar
• Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996;14(1):33–38. Available from: https://linkinghub.elsevier.com/retrieve/pii/0263785596000185.
   PubMedGoogle Scholar
• Hou T, Wang J, Li Y, et al. Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf. Model. 2011;51(1):69–82.
   PubMed Web of Science ®Google Scholar
• Homeyer N, Gohlke H. Free energy calculations by the Molecular Mechanics Poisson-Boltzmann surface Area method. Mol Inform. 2012;31(2):114–122.
   PubMed Web of Science ®Google Scholar
• Fornili A, Autore F, Chakroun N, et al. Protein-water interactions in MD simulations: POPS/POPSCOMP solvent accessibility analysis, solvation forces and hydration sites. Methods Mol Biol. 2012;819:375–392. Available from: http://link.springer.com/https://doi.org/10.1007/978-1-61779-465-0_23.
   PubMedGoogle Scholar
• Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin. Drug Discov. 2015;10(5):449–461. Available from: http://www.tandfonline.com/doi/full/https://doi.org/10.1517/17460441.2015.1032936.
   PubMed Web of Science ®Google Scholar